Curaleaf International, in Partnership with Jupiter Research, Secures EU Medical Device Certification for Europe's First Handheld Liquid Inhalation Device

Rhea-AI Summary

Curaleaf International and Jupiter Research (TLLTF) have secured EU medical device certification for Europe's first handheld liquid inhalation device designed for medical cannabis administration. The device, certified as a Class IIa medical device under EU Regulation 2017/745, features a magnetic snap-in cartridge and rechargeable power supply for consistent cannabinoid delivery.

The certification enables commercialization across multiple global markets, including European countries, the UK, Canada, and Australasia. The device's technical file and EU Declaration of Conformity were approved by an EU Notified Body, validating its quality, safety, and clinical effectiveness.

Positive

• First EU-certified handheld liquid inhalation device for medical cannabis in Europe
• Certification enables market access across multiple global regions including Europe, UK, Canada, and Australasia
• Partnership between Curaleaf and Jupiter Research strengthens market position
• Device meets highest regulatory standards for medical devices in Europe

Negative

• None.

News Market Reaction

+14.86%

1 alert

+14.86% News Effect

On the day this news was published, TLLTF gained 14.86%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

LONDON, May 12, 2025 /PRNewswire/ -- Curaleaf International, part of Curaleaf Holdings, Inc. (TSX: CURA) in collaboration with Jupiter Research LLC, a subsidiary of TILT Holdings Inc. ("TILT") (Cboe CA: TILT) (OTCPK: TLLTF), has secured regulatory approval for the first handheld liquid inhalation device designed for precise medical cannabis administration. This EU medical device certification (Regulation (EU) 2017/745) paves the way for improved patient options and a new era of innovation in medical cannabis delivery.

The liquid inhalation device is now certified as a Class IIa medical device, meeting rigorous European regulatory standards. The device includes a magnetic snap-in cartridge and a rechargeable power supply, engineered to provide a consistent and controlled cannabinoid delivery. A comprehensive technical file and full EU Declaration of Conformity were assessed and approved by a recognised EU Notified Body, validating the device's quality, safety, and clinical robustness.

EU certification supports deployment in multiple global markets and once commercialised, will enable healthcare professionals to recommend the device offered by Curaleaf International in countries including European countries, the UK, Canada, and regions across Australasia.

Boris Jordan, Chairman and CEO of Curaleaf, commented on this achievement:
"Achieving EU medical certification is more than a regulatory milestone—it's a signal that medical cannabis innovation is moving into the mainstream of global healthcare. We're proud to offer a device that meets the highest standards of safety and quality, and we look forward to supporting patients and healthcare providers across Europe and beyond with a new, accurate and discrete option for treatment."

Echoing this sentiment, TILT's Chief Executive Officer Tim Conder, added:
"Partnering with Curaleaf International on this project has been a natural extension of our long-standing partnership in the US. By delivering industry-leading, user-friendly solutions, our collaboration exemplifies how technology can revolutionise healthcare. Achieving EU medical certification on IP developed by our subsidiary Jupiter Research, validates the robustness of our engineering and R&D functions and sets a new benchmark for the industry."

This development reinforces Curaleaf International's role at the forefront of advancing access to legal, high-quality cannabis treatments across Europe and other international markets.

About Curaleaf International
Curaleaf International is shaping the future of cannabis through its commitment to research and product excellence. Powered by a strong presence at all stages of the supply chain, its unique distribution network throughout Europe, Canada and Australasia brings together pioneering research with cutting-edge cultivation, extraction, and production. Amidst a rapid growth trajectory, the emphasis on quality and expertise aims to ensure the delivery of safe and legal cannabis.

Curaleaf International's network includes a clinic, pharmacy, and laboratory in the UK; cultivation and EU-GMP processing facilities in Portugal; an EU-GMP processing, quality assurance and research site in Spain; Four20 Pharma wholesaler and distributor in Germany; a Polish wholesaler and clinic; and the EU-GMP producer Northern Green Canada.

Curaleaf International is part of Curaleaf Holdings, Inc., a leading international producer and distributor of consumer cannabis products.

About TILT and Jupiter Research
TILT Holdings manages a diverse portfolio of companies in the cannabis industry, encompassing technology, hardware, cultivation, and production. Its core business, Jupiter Research LLC, is a wholly owned subsidiary and a global distribution leader in the vaporization segment. Jupiter is dedicated to hardware design, research, development, and distribution to support cannabis brands and retailers across the United States, Canada, South America, and the European Union. Additionally, TILT is a multi-state operator, with cultivation and production facilities in three states under the Commonwealth Alternative Care and Standard Farms brands. For more information, visit www.tiltholdings.com.

Media Contact:

Curaleaf International:
Beth Sweet-Escott
Head of Communications, Curaleaf International
media@curaleafint.com 

TILT:
Lynn Ricci
VP of Investor Relations & Corporate Communications, TILT Holdings Inc.
lricci@tiltholdings.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/curaleaf-international-in-partnership-with-jupiter-research-secures-eu-medical-device-certification-for-europes-first-handheld-liquid-inhalation-device-302451697.html

SOURCE Curaleaf International

FAQ

What certification did TLLTF receive for its medical cannabis device in Europe?

TLLTF's Jupiter Research, in partnership with Curaleaf International, received EU medical device certification (Regulation EU 2017/745) for their handheld liquid inhalation device, classified as a Class IIa medical device.

What markets can TLLTF's new medical cannabis device be sold in?

The EU-certified device can be commercialized in European countries, the UK, Canada, and regions across Australasia.

What are the key features of TLLTF's new medical cannabis inhalation device?

The device features a magnetic snap-in cartridge and rechargeable power supply, designed to provide consistent and controlled cannabinoid delivery.

Who partnered with TLLTF to develop the EU-certified medical cannabis device?

Jupiter Research (TLLTF) partnered with Curaleaf International, a part of Curaleaf Holdings, to develop and certify the medical cannabis inhalation device.